Stocks Buzz: American International Group, Inc. (AIG), Zoetis Inc. (ZTS), Facebook, Inc. (FB)

American International Group, Inc. (AIG) managed to rebound with the stock climbing 2.33% or $1.42 to close the day at $62.27 on light trading volume of 14.24M shares, compared to its three month average trading volume of 5.71M. The New York New York 10038 based company has been outperforming the property & casualty insurance group over the past 52 weeks, with the stock gaining 22.64%, compared to the industry which has advanced 27.04% over the same period. With RSI of 36.9, the stock should still continue to rise and get closer to its one year target estimate of $72, making it a hold for now.

American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. The company operates through two segments, Commercial Insurance and Consumer Insurance. The company’s Commercial Insurance segment offers general liability, commercial automobile liability, workers’ compensation, excess casualty, and crisis management causality insurance products, as well as various risk-sharing and other customized structured programs; commercial, industrial, and energy-related property insurance products; aerospace, environmental, political risk, trade credit, surety, and marine insurance products; various insurance products for small and medium sized enterprises; and professional liability insurance products. It also provides mortgage guaranty insurance; stable value wrap products, and structured settlement and terminal funding annuities; and corporate- and bank-owned life insurance and guaranteed investment contracts. This segment sells its products through independent retail and wholesale brokers, agency network, specialized marketing and consulting firms, and structured settlement brokers. Its Consumer Insurance segment offers retirement products, such as fixed annuities, and immediate and deferred income annuities; variable and fixed index annuities; and mutual funds, and plan administrative and compliance services. This segment’s products also include term and whole life, cancer, and critical illness insurance products; personal accident and supplemental health products; travel insurance products and services; automobile and homeowners, and extended warranty insurance; and identity theft and credit card protection products. It sells its products through agents, direct marketing, independent marketing organizations, financial advisors, banks, wirehouses, and broker-dealers. The company was founded in 1919 and is based in New York, New York.

Zoetis Inc. (ZTS) retreated with the stock falling -4.3% or $-2.37 to close at $52.78 on light trading volume of 12.88M compared its three months average trading volume of 3.02M. The Florham Park New Jersey 07932 based company operating under the Drugs – Generic industry has been trending up for the last 52 weeks, with the shares price now 26.63% up for the period and down by -1.21% so far this year. With price target of $58.07 and a 35.23% rebound from 52-week low, Zoetis Inc. has plenty of upside potential, making it a hold with a view buy.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

Facebook, Inc. (FB) managed to rebound with the stock climbing 0.3% or $0.4 to close the day at $133.84 on lower than average trading volume of 12.81M shares, compared to its three month average trading volume of 20.27M. The Menlo Park California 94025 based company has been outperforming the internet information providers companies by 14.1004% for last three months and its recent gains have pushed the stock slightly up 16.33% YTD, versus the internet information providers industry which is up 9.39% for the same period. The RSI of 65.58 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Facebook, Inc. provides various products to connect and share through mobile devices, personal computers, and other surfaces worldwide. Its solutions include Facebook Website and mobile application that enables people to connect, share, discover, and communicate each other on mobile devices and personal computers; Instagram, a mobile application that enables people to take photos or videos, customize them with filter effects, and share them with friends and followers in a photo feed or send them directly to friends; Messenger, a messaging application to communicate with people and businesses across platforms and devices; and WhatsApp Messenger, a mobile messaging application. The company also offers Oculus virtual reality technology and content platform, which allow people to enter an immersive and interactive environment to play games, consume content, and connect with others. As of December 31, 2016, it had approximately 1.23 billion daily active users. Facebook, Inc. was founded in 2004 and is headquartered in Menlo Park, California.

 

Investor’s Alert: Zoetis Inc. (ZTS), The Kraft Heinz Company (KHC), Ventas, Inc. (VTR)

Zoetis Inc. (ZTS) continued its downward trend with the stock declining -0.22% or $-0.12 to close the day at $55.02 on higher than average trading volume of 5.22M shares, compared to its three month average trading volume of 3M. The Florham Park New Jersey 07932 based company has been outperforming the drugs – generic companies by 8.8156% for last three months and its recent gains have pushed the stock slightly up 2.99% YTD, versus the drugs – generic industry which is up 12.42% for the same period. The RSI of 58.37 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

The Kraft Heinz Company (KHC) had a light trading with around 2.32M shares changing hands compared to its three month average trading volume of 2.77M. The stock traded between $90.1 and $91.06 before closing at the price of $90.81 with 0.25% change on the day. The Pittsburgh Pennsylvania 15222 based company is currently trading 30.04% above its 52 week low of $71.02 and 0.23% above its 52 week high of $91.06. Both the RSI indicator and target price of 71.12 and $90.29 respectively, lead us to believe that it could drop over the coming weeks.

The Kraft Heinz Company manufactures and markets food and beverage products in the United States, Canada, Europe, and rest of world. The company’s products include condiments and sauces, cheese and dairy products, meals, meats, refreshment beverages, coffee, snack nuts, dressings, packaged dinners, infant/nutrition products, and other grocery products. It offers its products under various brand names, including Kraft, Oscar Mayer, Heinz, Planters, Velveeta, Philadelphia, Lunchables, Maxwell House, Capri Sun, Ore-Ida, Kool-Aid, Jell-O, Cracker Barrel, Tassimo, Plasmon, Lea & Perrins, ABC, Master, Quero, Golden Circle, Wattie’s, and Complan. The Kraft Heinz Company sells its products through independent brokers, agents and distributors to chain, wholesale, cooperative and independent grocery accounts, convenience stores, drug stores, value stores, bakeries, pharmacies, mass merchants, club stores, hotels, restaurants, hospitals, health care facilities, and certain government agencies, as well as through its own sales organizations. The company was formerly known as H.J. Heinz Holding Corporation and changed its name to The Kraft Heinz Company in July 2015. The Kraft Heinz Company was founded in 2013 and is headquartered in Pittsburgh, Pennsylvania.

Ventas, Inc. (VTR) traded within a range of $61.5 to $62.8 after opening the day at $62.8. The company has seen its stock decrease in value by -1.41% so far this year. The stock was down close to -1.85% on light volume in last trading session and closed at $61.64 per share. After the recent fall, the stock is currently holding -17.83% below its 52 week high of $76.8 and 34.77% above its 12-month low of $49.73. The shares are up by over 6.29% in the last three months, and the RSI indicator value of 50.14 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, management, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities including hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities. Ventas, Inc. was founded in 1983 and is based in Chicago, Illinois with additional offices in Irvine, California; Louisville, Kentucky; Charlotte, North Carolina; and Dallas, Texas.

 

Stocks Highlights: Walgreens Boots Alliance, Inc. (WBA), Zoetis Inc. (ZTS), V.F. Corporation (VFC)

Walgreens Boots Alliance, Inc. (WBA) had a active trading with around 4.4M shares changing hands compared to its three month average trading volume of 3.96M. The stock traded between $81.95 and $83.46 before closing at the price of $83.31 with 1.13% change on the day. The Deerfield Illinois 60015 based company is currently trading 14.86% above its 52 week low of $75.74 and -5.33% below its 52 week high of $88. Both the RSI indicator and target price of 55.42 and $94.55 respectively, lead us to believe that it should be put on hold over the coming weeks.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics. It also provides specialty pharmacy services; and manages in-store clinics. As of August 31, 2016, this segment operated 8,175 retail stores under the Walgreens and Duane Reade brands in the United States; and 7 specialty pharmacies, as well as approximately 400 in-store clinic locations. The Retail Pharmacy International segment sells prescription drugs; and health, beauty, toiletry, and other consumer products through its pharmacy-led health and beauty stores, as well as through boots.com. It is also involved in optical practice and related contract manufacturing operations. This segment operated 4,673 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 636 optical practices. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in France, the United Kingdom, Germany, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

Zoetis Inc. (ZTS) managed to rebound with the stock declining -0.41% or $-0.23 to close the day at $55.73 on active trading volume of 4.31M shares, compared to its three month average trading volume of 2.95M. The Florham Park New Jersey 07932 based company has been outperforming the drugs – generic group over the past 52 weeks, with the stock gaining 42.75%, compared to the industry which has advanced 0.11% over the same period. With RSI of 69.64, the stock should still continue to rise and get closer to its one year target estimate of $58.07, making it a hold for now.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

V.F. Corporation (VFC) shares were up in last trading by 1.72% to $50.32. It experienced higher than average volume on day. The stock increased in value by almost 1.53% over the past week and fell -4.19% in the past month. It is currently trading -5.24% below its 50 day moving average and -12.81% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -23.31% decrease in value from its one year high of $67.1. The RSI indicator value of 42.7, lead us to believe that it is a hold for now.

V.F. Corporation engages in the design, production, procurement, marketing, and distribution of branded lifestyle apparel, footwear, and related products in the United States and Europe. The company primarily offers outdoor apparel, footwear and equipment, youth culture/action sports-inspired footwear, handbags, luggage, backpacks, totes, accessories, surfing-inspired footwear, merino wool socks, women’s activewear, and travel accessories under the The North Face, Vans, Timberland, Kipling, Napapijri, Jansport, Reef, Smartwool, Eastpak, lucy, and Eagle Creek brands. It also provides denim, casual apparel, footwear, and accessories under the Wrangler, Lee, Lee Casuals, Riders by Lee, Rustler, Timber Creek by Wrangler, and Rock & Republic brands. In addition, the company offers occupational, protective occupational, athletic, licensed athletic, and licensed apparel products under the Red Kap, Bulwark, Horace Small, Majestic, MLB, NFL, and Harley-Davidson brands; sportswear apparel, luggage, and accessories under the Nautica brand; and handbags, luggage, backpacks, totes, and accessories under the Kipling brand. Further, it provides premium denim apparel, footwear, and accessories under the 7 For All Mankind, Splendid, and Ella Moss brands. The company sells its products primarily to specialty stores, department stores, national chains, and mass merchants, as well as sells through company operated stores, concession retail stores, and e-commerce sites. V.F. Corporation was founded in 1899 and is headquartered in Greensboro, North Carolina.

 

Stocks Buzz: The PNC Financial Services Group, Inc. (PNC), CA, Inc. (CA), Zoetis Inc. (ZTS)

The PNC Financial Services Group, Inc. (PNC) continued its downward trend with the stock declining -0.01% or $-0.01 to close the day at $121.46 on light trading volume of 2.89M shares, compared to its three month average trading volume of 3.08M. The Pittsburgh Pennsylvania 15222 based company has been outperforming the money center banks group over the past 52 weeks, with the stock gaining 51.28%, compared to the industry which has advanced 25.8% over the same period. With RSI of 58.2, the stock should still continue to rise and get closer to its one year target estimate of $124.38, making it a hold for now.

The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States and internationally. The company’s Retail Banking segment offers deposit, lending, brokerage, investment management, and cash management services to consumer and small business customers through branch network, ATMs, call centers, online banking, and mobile channels. As of March 31, 2016, this segment operated a network of 2,613 branches and 8,940 ATMs. Its Corporate & Institutional Banking segment provides secured and unsecured loans, letters of credit, equipment leases, cash and investment management, receivables management, disbursement and funds transfer, information reporting, trade services, foreign exchange, derivatives, securities, loan syndications, mergers and acquisitions advisory, equity capital markets advisory, and related services for corporations, government, and not-for-profit entities. This segment also offers commercial loan servicing, and real estate advisory and technology solutions for the commercial real estate finance industry. The company’s Asset Management Group segment provides investment and retirement planning, customized investment management, private banking, tailored credit solutions, and trust management and administration for individuals and their families; multi-generational family planning products; and mutual funds and institutional asset management services. Its Residential Mortgage Banking segment offers first lien residential mortgage loans. The company’s BlackRock segment provides investment and risk management services to institutional and retail clients. Its Non-Strategic Assets Portfolio segment offers consumer residential mortgage, brokered home equity loans, and lines of credit, as well as commercial real estate loans and leases. The PNC Financial Services Group, Inc. was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.

CA, Inc. (CA) retreated with the stock falling -0.48% or $-0.15 to close at $31.34 on active trading volume of 2.88M compared its three months average trading volume of 2.69M. The New York New York 10022 based company operating under the Business Software & Services industry has been trending up for the last 52 weeks, with the shares price now 17.49% up for the period and down by -1.35% so far this year. With price target of $32.8 and a 20.59% rebound from 52-week low, CA, Inc. has plenty of upside potential, making it a hold with a view buy.

CA, Inc. provides information technology (IT) management software and solutions that help organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally. The company operates through three segments: Mainframe Solutions, Enterprise Solutions, and Services. The Mainframe Solutions segment’s products portfolio include databases and database management, systems and operations management, application development, and security and compliance. The Enterprise Solutions segment provides products that are designed for distributed and cloud computing environments and run on industry standard servers. It offers Agile management solutions, which enables customers to plan and manage software development process and IT services delivery; DevOps solutions comprising a range of solutions that allow customers to deliver and manage applications and IT infrastructure; and security solutions, such as identity-centric security portfolio that allows customers to manage identities and regulate access from the device to the data center. The Services segment offers consulting, implementation, application management services, education, and support services to commercial and government customers. The company serves banks, insurance companies, other financial services providers, government agencies, global service providers, telecommunication providers, manufacturers, technology companies, retailers, educational organizations, and health care institutions. CA, Inc. sells its solutions through direct sales force, as well as indirectly through its partners. The company was formerly known as CA Technologies and changed its name to CA, Inc. in 2006. CA, Inc. was founded in 1974 and is headquartered in New York, New York.

Zoetis Inc. (ZTS) failed to extend gains with the stock declining -0.04% or $-0.02 to close the day at $55.96 on lower than average trading volume of 2.88M shares, compared to its three month average trading volume of 3.01M. The Florham Park New Jersey 07932 based company has been outperforming the drugs – generic companies by 12.0384% for last three months and its recent gains have pushed the stock slightly up 4.75% YTD, versus the drugs – generic industry which is up 9.7% for the same period. The RSI of 71.87 indicates the stock is overbought at the current levels, sell for now.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

 

Momentum Stocks: Zoetis Inc. (ZTS), Colgate-Palmolive Company (CL), Intercontinental Exchange, Inc. (ICE)

Zoetis Inc. (ZTS) retreated with the stock falling -0.27% or $-0.15 to close at $55.77 on light trading volume of 2.88M compared its three months average trading volume of 3.14M. The Florham Park New Jersey 07932 based company operating under the Drugs – Generic industry has been trending up for the last 52 weeks, with the shares price now 37.44% up for the period and up by 4.39% so far this year. With price target of $57.53 and a 46.96% rebound from 52-week low, Zoetis Inc. has plenty of upside potential, making it a hold with a view buy.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

Colgate-Palmolive Company (CL) had a light trading with around 2.87M shares changing hands compared to its three month average trading volume of 3.95M. The stock traded between $65.45 and $66.08 before closing at the price of $65.49 with -0.73% change on the day. The New York New York 10022 based company is currently trading 4.6% above its 52 week low of $63.43 and -12.14% below its 52 week high of $75.38. Both the RSI indicator and target price of  and $69.69 respectively, lead us to believe that it could rise over the coming weeks.

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Intercontinental Exchange, Inc. (ICE) saw its value decrease by -0.05% as the stock dropped $-0.03 to finish the day at a closing price of $58.51. The stock was higher in trading and has fluctuated between $45.44-$59.86 per share for the past year. The shares, which traded within a range of $58.12 to $58.57 during the day, are up by 8.88% in the past three months and up by 5.83% over the past six months. It is currently trading 1.8% above its 20 day moving average and 2.27% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $64.58 a share over the next twelve months. The current relative strength index (RSI) reading is 59.98.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Intercontinental Exchange, Inc. operates regulated exchanges, clearing houses, and listings venues for financial and commodity markets in the United States, the United Kingdom, Continental Europe, Asia, Israel, and Canada. The company operates marketplaces for trading and clearing an array of derivatives and securities contracts across various asset classes, including energy and agricultural commodities, interest rates, equities, equity derivatives, credit derivatives, bonds, and currencies. It primarily provides trade execution, listing, price discovery and transparency, trade processing and repositories, clearing, benchmark administration, and market data services. The company operates exchanges and marketplaces, such as ICE Futures Europe, ICE Futures U.S., ICE Futures Canada, ICE Endex, NYSE Amex Options, NYSE Arca Options, and ICE Futures Singapore, as well as over-the-counter markets for physical energy and credit default swaps, and central counterparty clearing houses. It serves financial institutions, money managers, trading firms, commodity producers and consumers, institutional and individual investors, and other business entities. The company was founded in 2000 and is headquartered in Atlanta, Georgia.

 

Stock’s Trend Analysis Report: IDEXX Laboratories, Inc. (IDXX), Biogen Inc. (BIIB), Zoetis Inc. (ZTS)

IDEXX Laboratories, Inc. (IDXX) climbed 13.25% during last trading as the stock added $16.27 to finish the day at $139.07 with about 2.76M shares changing hands, compared to its three month average trading volume of 923.98K. The $12.47B market cap company, which fluctuated between $125.02 and $139.9 during the day, currently situated 108.13% above its 52 week low of $66.82 and 12.83% away from its one year high of $139.9. The RSI of 81.23 indicates the stock is overbought at the current levels, sell for now.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management systems and services, and digital imaging systems for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic, health-monitoring, and food safety testing products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Biogen Inc. (BIIB) dropped $-17.46 to close the day at a new closing price of $264.23, a -6.2% decrease in value from its previous closing price that moved the stock 18.48% above its 52 week low of $223.02. A total of 2.73M shares exchanged hands during the day compared with its three month average trading volume of 1.83M. The stock, which fluctuated between $260.5 and $264.52 during the day, currently situated -20.81% below its 52 week high. The stock is down by -9.42% in the past one month and down by -6.49% over the past three months. With a one year target estimate of $333.25 and RSI of 31.16, the stock still has upside potential, making it a hold for now.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat hemophilia A for control of bleeding episodes; ALPROLIX to treat hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL); GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company’s products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer’s disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS – DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson’s disease; and BIIB063 for sjogren’s syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc.; and an agreement with Siemens Healthineers to develop new magnetic resonance imaging tools for multiple sclerosis. It offers products through its sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Zoetis Inc. (ZTS) had a light trading with around 2.72M shares changing hands compared to its three month average trading volume of 3.27M. The stock traded between $54.72 and $55.72 before closing at the price of $55.7 with 0.69% change on the day. The Florham Park New Jersey 07932 based company is currently trading 46.77% above its 52 week low of $38.26 and 0.63% above its 52 week high of $55.72. Both the RSI indicator and target price of 73.99 and $57.53 respectively, lead us to believe that it could drop over the coming weeks.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

 

Stocks Buzz: Ventas, Inc. (VTR), Zoetis Inc. (ZTS), T-Mobile US, Inc. (TMUS)

Ventas, Inc. (VTR) continued its upward trend with the stock climbing 0.39% or $0.24 to close the day at $61.67 on active trading volume of 2.54M shares, compared to its three month average trading volume of 2.28M. The Chicago Illinois 60654 based company has been outperforming the reit – healthcare facilities group over the past 52 weeks, with the stock gaining 16.51%, compared to the industry which has advanced 12.72% over the same period. With RSI of 51.84, the stock should still continue to rise and get closer to its one year target estimate of $64.31, making it a hold for now.

Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, management, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities including hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities. Ventas, Inc. was founded in 1983 and is based in Chicago, Illinois with additional offices in Irvine, California; Louisville, Kentucky; Charlotte, North Carolina; and Dallas, Texas.

Zoetis Inc. (ZTS) grew with the stock adding 1.23% or $0.67 to close at $54.94 on active trading volume of 3.62M compared its three months average trading volume of 3.38M. The Florham Park New Jersey 07932 based company operating under the Drugs – Generic industry has been trending up for the last 52 weeks, with the shares price now 28.93% up for the period and up by 2.84% so far this year. With price target of $57.53 and a 44.77% rebound from 52-week low, Zoetis Inc. has plenty of upside potential, making it a hold with a view buy.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

T-Mobile US, Inc. (TMUS) managed to rebound with the stock climbing 1.86% or $1.14 to close the day at $62.27 on higher than average trading volume of 4.5M shares, compared to its three month average trading volume of 3.95M. The Bellevue Washington 98006 based company has been outperforming the wireless communications companies by 26.1319% for last three months and its recent gains have pushed the stock slightly up 8.28% YTD, versus the wireless communications industry which is up 7.02% for the same period. The RSI of 64.66 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

T-Mobile US, Inc., together with its subsidiaries, provides mobile communications services for consumers and businesses in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, including smartphones, tablets, and other mobile communication devices, as well as accessories that are manufactured by various suppliers. The company offers services, devices, and accessories under the T-Mobile and MetroPCS brands through its owned and operated retail stores, as well as through its Websites. T-Mobile US, Inc. also sells its devices and accessories to dealers and other third party distributors for resale through independent third-party retail outlets and various third-party Websites. It delivers wireless services to approximately 65.5 million customers. The company was founded in 1994 and is headquartered in Bellevue, Washington. T-Mobile US, Inc. operates as a subsidiary of Deutsche Telekom Holding B.V.

 

Traders Watch list: Zoetis Inc. (ZTS), State Street Corporation (STT), United Parcel Service, Inc. (UPS)

Zoetis Inc. (ZTS) saw its value increase by 1.5% as the stock gained $0.81 to finish the day at a closing price of $54.65. The stock was lighter in trading and has fluctuated between $38.26-$54.72 per share for the past year. The shares, which traded within a range of $53.97 to $54.72 during the day, are up by 12.5% in the past three months and up by 9.6% over the past six months. It is currently trading 1.9% above its 20 day moving average and 5.23% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $57.53 a share over the next twelve months. The current relative strength index (RSI) reading is 67.28.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

State Street Corporation (STT) shares were down in last trading by -0.76% to $76. It experienced higher than average volume on day. The stock decreased in value by almost -3.81% over the past week and fell -3.33% in the past month. It is currently trading -4.02% below its 50 day moving average and 12.3% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -8.97% decrease in value from its one year high of $83.49. The RSI indicator value of 38.92, lead us to believe that it is a hold for now.

State Street Corporation, through its subsidiaries, provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, including custody; product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; cash management; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics. It also provides investment management services, such as investment management, investment research, and investment advisory services to corporations, public funds, and other sophisticated investors, as well as offers active and passive asset management strategies across equity, fixed-income, and cash asset classes. The company offers its products and services to mutual funds, collective investment funds and other investment pools, corporate and public retirement plans, insurance companies, foundations, endowments, and investment managers. State Street Corporation was founded in 1792 and is headquartered in Boston, Massachusetts.

United Parcel Service, Inc. (UPS) traded within a range of $116.59 to $118.19 after opening the day at $117. The company has seen its stock increase in value by 3.01% so far this year. The stock was up close to 0.99% on light volume in last trading session and closed at $118.09 per share. After the recent gain, the stock is currently holding -1.95% below its 52 week high of $120.44 and 34.77% above its 12-month low of $92.04. The shares are up by over 9.49% in the last three months, and the RSI indicator value of 65.81 is neither bullish nor bearish, tempting investors to stay on the sidelines.

United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. It operates in three segments: U.S. Domestic Package, International Package, and Supply Chain & Freight. The U.S. Domestic Package segment offers time-definite delivery of letters, documents, small packages, and palletized freight through air and ground services in the United States. The International Package segment provides guaranteed day and time-definite international shipping services in Europe, the Asia Pacific, Canada and Latin America, the Indian sub-continent, the Middle East, and Africa. It offers guaranteed time-definite express options, including Express Plus, Express, and Express Saver. The Supply Chain & Freight segment offers international air and ocean freight forwarding, customs brokerage, truckload freight brokerage, distribution and post-sales services, and mail and consulting services in approximately 220 countries and territories; and less-than-truckload and truckload services to customers in North America. The company also offers shipping, visibility, and billing technologies; and insurance, financing, and payment services. It operates a fleet of approximately 110,000 package cars, vans, tractors, and motorcycles; and owns 33,000 containers used to transport cargo in its aircraft. United Parcel Service, Inc. was founded in 1907 and is headquartered in Atlanta, Georgia.

 

3 Stocks in Focus: Apache Corporation (APA), Exelon Corporation (EXC), Zoetis Inc. (ZTS)

Apache Corporation (APA) climbed 0.77% during last trading as the stock added $0.47 to finish the day at $61.43 with about 3.91M shares changing hands, compared to its three month average trading volume of 3.19M. The $23.46B market cap company, which fluctuated between $60.85 and $61.92 during the day, currently situated 88.04% above its 52 week low of $33.23 and -10.62% away from its one year high of $69. The RSI of 39.16 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Apache Corporation, an independent energy company, explores, develops, and produces natural gas, crude oil, and natural gas liquids. It operates onshore and offshore assets primarily in the Permian Basin, the Anadarko basin in western Oklahoma, the Texas Panhandle, and Gulf Coast areas of the United States, as well as in Western Canada and Gulf of Mexico. The company also operates assets in Egypt and the United Kingdom in the North Sea. As of December 31, 2015, it had total estimated proved reserves of 794 million barrels of crude oil, 198 million barrels of natural gas liquids, and 3.4 trillion cubic feet of natural gas. Apache Corporation was founded in 1954 and is based in Houston, Texas.

Exelon Corporation (EXC) gained $0.22 to close the day at a new closing price of $35.35, a 0.63% increase in value from its previous closing price that moved the stock 35.27% above its 52 week low of $27.85. A total of 3.91M shares exchanged hands during the day compared with its three month average trading volume of 6.38M. The stock, which fluctuated between $35.18 and $35.45 during the day, currently situated -4.44% below its 52 week high. The stock is up by 0.11% in the past one month and up by 9.35% over the past three months. With a one year target estimate of $38.42 and RSI of 53.69, the stock still has upside potential, making it a hold for now.

Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States and Canada. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, as well as wind and solar facilities. The company also sells renewable energy and other energy-related products and services; and engages in natural gas and oil exploration and production activities, as well as sells electricity and natural gas to wholesale and retail customers. In addition, it is involved in the purchase and regulated retail sale of electricity, and the provision of electricity transmission and distribution services to retail customers in northern Illinois, southeastern Pennsylvania, and central Maryland. Further, the company engages in the purchase and regulated retail sale of natural gas, and the provision of gas distribution services to retail customers in the Pennsylvania counties surrounding the City of Philadelphia, as well as in central Maryland, including the City of Baltimore. It serves distribution utilities, municipalities, cooperatives, and financial institutions, as well as commercial, industrial, governmental, and residential customers. The company was founded in 1887 and is headquartered in Chicago, Illinois.

Zoetis Inc. (ZTS) had a active trading with around 3.86M shares changing hands compared to its three month average trading volume of 3.4M. The stock traded between $53.73 and $54.29 before closing at the price of $54 with 0.41% change on the day. The Florham Park New Jersey 07932 based company is currently trading 42.29% above its 52 week low of $38.26 and -1.12% below its 52 week high of $54.72. Both the RSI indicator and target price of 62.5 and $57.4 respectively, lead us to believe that it should be put on hold over the coming weeks.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

 

Stocks in Focus: Zoetis Inc. (ZTS), Arena Pharmaceuticals, Inc. (ARNA), EP Energy Corporation (EPE)

Zoetis Inc. (ZTS) had a light trading with around 2.49M shares changing hands compared to its three month average trading volume of 3.39M. The stock traded between $53.46 and $53.99 before closing at the price of $53.78 with 0.06% change on the day. The Florham Park New Jersey 07932 based company is currently trading 41.71% above its 52 week low of $38.26 and -1.52% below its 52 week high of $54.72. Both the RSI indicator and target price of 61.03 and $57.4 respectively, lead us to believe that it should be put on hold over the coming weeks.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia, pain management, and the diagnosis of diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories comprising nutritionals and agribusiness services, as well as products and services in complementary areas consisting of biodevices, diagnostics, and genetics. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

Arena Pharmaceuticals, Inc. (ARNA) continued its upward trend with the stock climbing 2.86% or $0.04 to close the day at $1.44 on active trading volume of 2.46M shares, compared to its three month average trading volume of 1.64M. The San Diego California 92121 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -12.73%, compared to the industry which has advanced 1.12% over the same period. With RSI of 49.78, the stock should still continue to rise and get closer to its one year target estimate of $3.75, making it a hold for now.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company’s products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.

EP Energy Corporation (EPE) shares were up in last trading by 1.23% to $5.75. It experienced lighter than average volume on day. The stock decreased in value by almost -5.58% over the past week and fell -10.71% in the past month. It is currently trading 1.5% above its 50 day moving average and 18.31% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -23.23% decrease in value from its one year high of $7.49. The RSI indicator value of 45.29, lead us to believe that it is a hold for now.

EP Energy Corporation, an independent exploration and production company, acquires and develops unconventional onshore oil and natural gas properties in the United States. The company has interests in various properties covering an area of approximately 487,000 net acres located in the areas of Eagle Ford Shale, South Texas; the Wolfcamp Shale, the Permian Basin, West Texas; the Altamont Field, the Uinta Basin, Northeastern Utah; and the Haynesville Shale, North Louisiana. It primarily sells its oil and natural gas production to third parties. As of December 31, 2015, the company had proved reserves of 546.0 million barrels of oil equivalent. EP Energy Corporation is headquartered in Houston, Texas.